PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6506836

[Myoglobin behavior with hexoprenaline and beta blockade].

W Lechner·G Daxenbichler
View original source ↗Export metadata ↓

Abstract

The addition of the calcium-antagonist Verapamil in order to antagonize myocardial side-effects under tokolysis with beta-mimetic agents was more and more critisized in the last time. We have therefore combined the tocolytic agent Hexoprenalin with the beta 1-blocking agent Metroprolol in 24 patients and have analysed the myoglobin level before as well as two and four hours after the beginning of tokolysis. There was no increase of serum-myoglobin seen under this tocolytic regime.

Explore related subjects

Drug Therapy, CombinationFemaleHexoprenalineHumansMetoprololMyoglobinObstetric Labor, PrematurePhenethylaminesPregnancyEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W Lechner, G Daxenbichler. [Myoglobin behavior with hexoprenaline and beta blockade].. https://pubmed.ncbi.nlm.nih.gov/6506836/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗